Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.40M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.58M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -11.77M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -8.57M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 35.24M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 28.62M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 576.89K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 20.67M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 14.57M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -8.94M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -8.68M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -359.06K | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 17.05M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$641.07M | -10.31 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$324.21M | -22.69 | -83.97% | ― | 1271.12% | 36.87% | |
46 Neutral | AU$147.84M | -6.94 | -81.03% | ― | -20.79% | 73.98% | |
44 Neutral | AU$189.42M | -7.27 | ― | ― | ― | 0.66% | |
44 Neutral | AU$108.11M | -13.24 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$293.01M | -30.08 | -89.70% | ― | 42.05% | -0.84% |
Orthocell Ltd Corporate Events
Orthocell reported record quarterly revenue of $3.2 million for the December 2025 quarter, its seventh consecutive quarter of record sales, driven by strong Remplir nerve repair product uptake in existing markets and initial U.S. sales. The company’s hybrid U.S. market entry strategy—combining specialist distributors with internal field leadership—is gaining traction, with distributor coverage now spanning more than 25 states, 23 hospital Value Analysis Committee approvals, and multiple medical education events completed, while Canadian market entry is underway. Supported by $49.4 million in cash reserves, no debt and an expected R&D tax refund, Orthocell is well positioned to accelerate Remplir adoption and pursue a step-change in revenue as it scales across North America.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell has disclosed a change in the interests of managing director Paul Anderson, who holds securities both directly and indirectly through family-related entities including the Elwing Superannuation Fund and the Elwing Family Trust. The filing shows that 126,580 short-term performance rights expiring in November 2027 have vested and been exercised into an equivalent number of ordinary shares at no cash consideration, reflecting the satisfaction of preset performance conditions and increasing Anderson’s direct equity exposure while reducing his performance rights balance; the move underscores ongoing alignment between executive remuneration and shareholder outcomes but does not involve any on-market trading or changes to contractual interests.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 217,742 fully paid ordinary shares for nil consideration following the exercise of an equivalent number of short‑term performance rights expiring in November 2027, and has confirmed that the issue was conducted without a disclosure document under the relevant Corporations Act provisions. The company stated it is compliant with its continuous disclosure and financial reporting obligations and that there is no excluded information to disclose, signalling a routine capital structure adjustment with no additional material information flagged for investors at this time.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has applied to the ASX for quotation of 217,742 new fully paid ordinary shares under its ticker OCC. The additional securities, issued on 22 December 2025 following the exercise or conversion of existing options or other convertible instruments, will modestly increase the company’s free float and share capital, offering existing holders greater liquidity while signalling continued utilisation of equity-based funding mechanisms.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has achieved a milestone in its U.S. commercial rollout of Remplir™, with 100 units sold in the $1.6 billion U.S. nerve repair market. This accomplishment reflects growing adoption fueled by a robust medical education campaign and a specialized distributor network. The company’s early success, including significant hospital VAC approvals, positions Remplir™ for future growth in both the U.S. and Canada, targeting a combined addressable market of $3.5 billion. Leveraging strong distribution frameworks and a debt-free financial position, Orthocell aims to accelerate its global market expansion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has submitted a regulatory application to the British Standards Institution for approval to distribute its nerve repair product, Remplir™, in the EU and UK markets, which represent a combined market size of US$750 million. The company expects to receive the necessary certifications by the third quarter of 2026, enabling it to expand its global market presence. The application is supported by strong clinical evidence, including an 81.1% treatment success rate from recent studies, positioning Remplir™ as a key player in nerve repair surgery. Orthocell’s strategy includes forming a panel of key opinion leaders and utilizing in-country distributors to drive market adoption, supported by a robust financial position with approximately $50 million in cash.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has achieved a significant milestone with the first commercial sales of its product, Remplir™, in Hong Kong, marking a crucial step in its Asian growth strategy. This expansion is part of Orthocell’s broader global commercialization plan, which includes sales in multiple countries and aims to establish Remplir as a standard in peripheral nerve repair. The company’s strategic entry into Hong Kong serves as a gateway to the Greater Bay Area, a major healthcare market, and is supported by partnerships with local distributors. With substantial financial resources and no debt, Orthocell is well-positioned to drive product adoption and revenue growth.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced a change in the director’s interest, specifically regarding Paul Anderson, who has been issued 52,078 Short-Term Performance Rights following shareholder approval. This adjustment in director’s interest reflects the company’s ongoing commitment to aligning management incentives with shareholder interests, potentially impacting the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited announced the issuance of 52,078 performance rights set to expire in November 2028, as part of an employee incentive scheme. This move is aimed at motivating and retaining talent within the company, potentially enhancing its operational capabilities and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the increasing adoption of its product, Remplir™, among Australian urologists for nerve-sparing prostate cancer surgeries, with approximately 100 surgeries conducted nationwide. This application aims to reduce complications such as erectile dysfunction and urinary incontinence, presenting a significant commercial opportunity for the company. Orthocell plans to expand its U.S. market from $1.6 billion to $2 billion by investing in further research and establishing a commercialization advisory board to support a targeted U.S. launch. The company is also compiling clinical data from initial procedures in Australia to bolster its scientific foundation for international market launches.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 230,770 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with their strategy to enhance financial resources for ongoing product development and market expansion, potentially strengthening their position in the regenerative medicine industry.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the quotation of 230,770 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 14, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the visibility and accessibility of its securities.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited announced the successful outcomes of its Annual General Meeting, where all resolutions, including a special resolution to amend the Constitution, were passed. This development signifies strong shareholder support and may enhance the company’s governance framework, potentially impacting its strategic direction and stakeholder relations positively.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited held its Annual General Meeting where the Chair and Managing Director addressed stakeholders. The company continues to expand its market presence with recent product approvals and initial sales in the US, enhancing its position in the regenerative medicine industry. This growth is supported by a network of specialist distributors and ongoing development of its tendon cell therapy in the US.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has expanded its distribution network in Canada by appointing a second distributor for its nerve repair device, Remplir™, achieving full national coverage in the US$75 million Canadian market. This strategic move enhances Orthocell’s market penetration, with first sales expected this quarter following a successful launch at a major medical conference. The new distributor, based in Ontario, will cover provinces outside Alberta and British Columbia, leveraging extensive experience in the nerve, spine, and orthopedic sectors. This expansion is part of Orthocell’s broader strategy to drive sales and establish strong distributor relationships globally, supported by a robust financial position and existing marketing and education teams.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has successfully completed the first surgical case using its Remplir™ nerve repair device in Hong Kong, marking a significant milestone in its Asia-Pacific commercialization strategy. The launch at the Hong Kong Orthopaedic Association’s Annual Congress, in partnership with local distributor MontsMed, positions Orthocell to penetrate the Greater Bay Area market, a region with substantial growth potential. With a strong financial position and strategic partnerships, Orthocell is poised to expand its global footprint and increase revenue, with upcoming sales in Canada and Thailand and continued momentum in the US market.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd announced a change in the director’s interest, with Michael McNulty acquiring 24,561 ordinary shares through an on-market purchase. This transaction reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Orthocell’s future growth and market positioning.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has appointed MontsMed as the exclusive distributor for its Remplir product in Hong Kong, marking a significant step in its Asian commercialization strategy. This move is expected to facilitate market access in the Guangdong-Hong Kong-Macao Greater Bay Area, a region with a population of around 100 million, and complements ongoing sales efforts in Singapore and anticipated market entry in Thailand. The company’s strategic expansion is supported by a robust financial position and the recent appointment of a Commercial Director to oversee operations in Asia.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the issuance of unquoted equity securities, specifically options expiring in 2028, as part of a previously disclosed transaction. This strategic move could potentially enhance the company’s financial flexibility and support its ongoing initiatives in the regenerative medicine sector, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 22,846,154 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with the company’s strategic efforts to enhance its financial standing and support ongoing negotiations with Hong Kong distributors. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, indicating compliance with regulatory requirements. This capital injection is expected to bolster Orthocell’s operations and potentially strengthen its position in the regenerative medicine industry.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the quotation of 22,846,154 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 24, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s capital structure and market presence, which could have significant implications for its stakeholders and industry positioning.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 150,000 fully paid ordinary shares at $0.48 each following the exercise of unlisted options, complying with relevant sections of the Corporations Act 2001. This issuance reflects the company’s ongoing efforts to strengthen its financial position and support its operations in the regenerative medicine sector, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the application for quotation of 150,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing growth initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has increased its equity stake in Marine Biomedical Pty Ltd to 12%, securing global distribution rights for PearlBone™, an innovative bone substitute made from sustainably sourced pearl shells. This strategic investment enhances Orthocell’s regenerative medicine portfolio and positions the company to capitalize on the US$1.6 billion bone substitute market, with expectations of significant value growth following regulatory approvals.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has issued a supplementary notice for its upcoming Annual General Meeting, scheduled for November 6, 2025. This notice includes additional resolutions, specifically the issuance of short-term performance rights to Mr. Paul Anderson or his nominees. Shareholders are advised to review this supplementary notice alongside the original notice to understand the new resolutions and their implications. The meeting will be held both in-person and online, and shareholders are encouraged to update their proxy votes if they wish to vote on the newly introduced resolutions.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced a proposed issue of securities, including options and ordinary shares, set to be issued on October 24, 2025. This move is likely aimed at raising capital to support the company’s ongoing projects and strategic initiatives, potentially strengthening its position in the regenerative medicine market and providing opportunities for growth and development.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has successfully raised $30 million through an institutional placement, attracting significant interest from US and international investors. The funds will be used to accelerate the US rollout of Remplir, expand manufacturing capacity, and advance clinical studies for its use in prostate cancer surgeries. The company is also investing in new regenerative medicine applications, positioning itself strongly in the global market with over $50 million in cash and no debt. This strategic financial move is expected to enhance Orthocell’s market position and drive growth, particularly in the US, where the company has already achieved significant milestones in its commercial operations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited, a company listed on the Australian Securities Exchange under the ticker OCC, has requested a trading halt on its securities. This halt is in place pending an announcement regarding a proposed capital raising. The trading halt is expected to remain until the company releases the announcement or until normal trading resumes on 17 October 2025. This move indicates a potential strategic financial maneuver by Orthocell, which could impact its market positioning and investor relations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.